Published results for Tris Pharma’s ADHD products for the treatment of ADHD in people 6 years and older
METHYLPHENIDATE EXTENDED-RELEASE ORAL SUSPENSION
Robb AS, Findling RL, Childress AC, Berry SA, Belden HW, Wigal SB. Efficacy, safety, and tolerability of a novel methylphenidate extended-release oral suspension (MEROS) in ADHD. J Atten Disord. 2017;21(14):1180-1191.See article >
Sallee FR, Palumbo DR, Abbas R, Berry SA, Puthili SP, Kathala KK. Effect of food intake on the pharmacokinetics of a novel methylphenidate extended-release oral suspension for attention deficit hyperactivity disorder. Clin Pharmacol Drug Dev. 2017;6(5):476-483.See article >
Wigal SB, Childress AC, Belden HW, Berry SA. NWP06, an extended-re/ease oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study. J Child Adolesc Psychopharmacol. 2013;23(1):3-10.See article >
Childress AC, Sallee FR, Berry SA. single-dose pharmacokinetics of nwp06, an extended-release methylphenidate suspension, in children and adolescents with ADHD. Postgrad Med. 2011;123(5):80-88.
Childress AC, Berry SA. The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. Postgrad Med. 2010;122(5):35-41.
METHYLPHENIDATE EXTENDED-RELEASE TABLET
Abbas R, Childress AC, Nagraj B, et al. Relative bioavailability of methylphenidate extended-release chewable tablets chewed versus swallowed whole. Clin Ther. 2018;40(5):733-740.
Wigal SB, Childress A, Berry SA, et al. Optimization of methylphenidate extended-release chewable tablet dose in children with ADHD: open-label dose optimization in a laboratory classroom study. J Child Adolesc Psychopharmacol. 2018;28(5):314-321.See article >
Wigal SB, Childress AC, Berry SA, et al. Efficacy and safety of a chewable methylphenidate extended-release tablet in children with attention deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2017 ;27(8):690-699.See article >
Abbas R, Palumbo D, Walters F, Belden H, Berry SA. Single-dose pharmacokinetic properties and relative bioavailability of a novel methylphenidate extended-release chewable tablet compared with immediate-release methylphenidate chewable tablet. Clin Ther. 2016;38(5):1151-1157.
AMPHETAMINE EXTENDED-RELEASE ORAL SUSPENSION
Pardo A, Kando JC, King TR, Rafla E, Herman BK. Single-dose pharmacokinetics of amphetamine extended-release tablets compared with amphetamine extended-release oral suspension. CNS Spectr. 2020;22:1-8.See article >
Herman BK, Bouhajib M, King TR, Kando JC, Pardo A. Single-dose pharmacokinetics of amphetamine extended-release oral suspension in healthy adults. J Atten Disord. 2019. doi:10.1177/1087054719841131.
Childress AC, Kando JC, King TR, Pardo A, Herman BK. Early-onset efficacy and safety pilot study of amphetamine extended-re/ease oral suspension in the treatment of children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2019;29(1):2-8.See article >
Childress AC, Wigal SB, Brams MN, et al. Efficacy and safety of amphetamine extended-release oral suspension in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2018;28(5):306-313.See article >
Please see Full Prescribing Information and Medication Guide for Dyanavel XR, Quillivant XR, and QuilliChew ER, including Boxed Warning about Abuse and Dependence.
ADHD, attention deficit hyperactivity disorder.
DYANAVEL is a registered trademark of Tris Pharma, Inc. Quillivant XR and QuilliChew ER are registered trademarks of NextWave Pharmaceuticals, Inc.
NextWave Pharmaceuticals, Inc. is a wholly owned subsidiary of Tris Pharma, Inc.
© 2021 Tris Pharma, Inc. All rights reserved. DXR.919.PR 11/21